Picropodophyllin inhibits epithelial ovarian cancer cells in vitro and in vivo

Biochemical and Biophysical Research Communications

Volumn 435, Issue 3, 2013, Pages 385-390

  Lu, Xiaosheng ^a   Wang, Ledan ^a   Mei, Jie ^a   Wang, Xin ^b   Zhu, Xueqiong ^a   Zhang, Qiong ^a   Lv, Jieqiang ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b WENZHOU CENTRAL HOSPITAL   (China)

Author keywords

Cisplatin; Insulin like growth factor 1 receptor; Ovarian carcinoma; Picropodophyllin

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; PICROPODOPHYLLIN; SODIUM CHLORIDE; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER SIZE; CELL GROWTH; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER TOXICITY; MOUSE; NEPHROTOXICITY; NONHUMAN; OVARY CANCER; OVARY CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GROWTH INHIBITORS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PODOPHYLLOTOXIN; TUMOR STEM CELL ASSAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS; MUS MUSCULUS;

EID: 84878964512     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.04.097     Document Type: Article

References (28)

1. Beauchamp M.C., Yasmeen A., Knafo A., et al. Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer. J. Oncol. 2010, 2010:257058.
2. Liu J., Matulonis U.A. New advances in ovarian cancer. Oncology 2010, 24:721-728.
3. Bookman M.A. Standard treatment in advanced ovarian cancer in 2005: the state of the art. Int. J. Gynecol. Cancer 2005, 15:212-220.
4. Doghman M., Axelson M., Lalli E. Potent inhibitory effect of the cyclolignan picropodophyllin (PPP) on human adrenocortical carcinoma cellsproliferation. Am. J. Cancer Res. 2011, 1:356-361.
5. Vasilcanu R., Vasilcanu D., Sehat B., et al. Insulin-like growth factor type-I receptor-dependent phosphorylation of extracellular signal-regulated kinase 1/2 but not Akt (protein kinase B) can be induced by picropodophyllin. Mol. Pharmacol. 2008, 73:930-939.
6. Liu L., Cao Y., Chen C., et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006, 66:11851-11858.
7. Girnita A., All-Ericsson C., Economou M.A., et al. The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells. Clin. Cancer Res. 2006, 12:1383-1391.
8. Kalli K.R., Falowo O.I., Bale L.K., et al. Functional insulin receptors on human epithelial ovarian carcinoma cells: implications for IGF-II mitogenic signaling. Endocrinology 2002, 143:3259-3267.
9. Gotlieb W.H., Bruchim I., Gu J., et al. Insulin-like growth factor receptor I targeting in epithelial ovarian cancer. Gynecol. Oncol. 2006, 100:389-396.
10. Klinakis A., Szabolcs M., Chen G., et al. Igf1r as a therapeutic target in a mouse model of basal-like breast cancer. Proc. Natl. Acad. Sci. USA 2009, 106:2359-2364.
11. Ohshima-Hosoyama S., Hosoyama T., Nelon L.D., et al. IGF-1 receptor inhibition by picropodophyllin in medulloblastoma. Biochem. Biophys. Res. Commun. 2010, 399:727-732.
12. Guha M., Srinivasan S., Biswas G., et al. Activation of a novel calcineurin-mediated insulin-like growth factor-1 receptor pathway, altered metabolism, and tumor cell invasion in cells subjected to mitochondrial respiratory stress. J. Biol. Chem. 2007, 282:14536-14546.
13. Laviola L., Natalicchio A., Giorgino F. The IGF-I signaling pathway. Curr. Pharm. Des. 2007, 13:663-669.
14. Shen M.R., Lin A.C., Hsu Y.M., et al. Insulin-like growth factor 1 stimulates KCl cotransport, which is necessary for invasion and proliferation of cervical cancer and ovarian cancer cells. J. Biol. Chem. 2004, 279:40017-40025.
15. Cao Z., Liu L.Z., Dixon D.A., et al. Insulin-like growth factor-I induces cyclooxygenase-2 expression via PI3K, MAPK and PKC signaling pathways in human ovarian cancer cells. Cell. Signal. 2007, 19:1542-1553.
16. Meng Q., Xia C., Fang J., et al. Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. Cell Signal. 2006, 18:2262-2271.
17. Baserga R., Peruzzi F., Reiss K. The IGF-1 receptor in cancer biology. Int. J. Cancer 2003, 107:873-877.
18. Ouban A., Muraca P., Yeatman T., et al. Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum. Pathol. 2003, 34:803-808.
19. Beauchamp M.C., Knafo A., Yasmeen A., et al. BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide. Gynecol. Oncol. 2009, 115:193-198.
20. Haluska P., Carboni J.M., Loegering D.A., et al. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Res. 2006, 66:362-371.
21. Economou M.A., Andersson S., Vasilcanu D., et al. Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma. Invest. Ophthalmol. Vis. Sci. 2008, 86:35-41.
22. Strömberg T., Ekman S., Girnita L., et al. IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood 2006, 107:669-678.
23. Kai K., D'Costa S., Sills R.C., et al. Inhibition of the insulin-like growth factor 1 receptor pathway enhances the antitumor effect of cisplatin in human malignant mesothelioma cell lines. Cancer Lett. 2009, 278:49-55.
24. Eckstein N., Servan K., Hildebrandt B., et al. Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. Cancer Res. 2009, 69:2996-3003.
25. Patel M., Smyth E., Chapman P.B., et al. Therapeutic implications of the emerging molecular biology of uveal melanoma. Clin. Cancer Res. 2011, 17:2087-2100.
26. Rybak L.P., Mukherjea D., Jajoo S., et al. Cisplatin ototoxicity and protection: clinical and experimental studie. Tohoku J. Exp. Med. 2009, 219:177-186.
27. Tsang R.Y., Al-Fayea T., Au H.J. Cisplatin overdose: toxicities and management. Drug Saf. 2009, 32:1109-1122.
28. Girnita A., Girnita L., del Prete F., et al. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res. 2004, 64:236-242.